GXO Logistics Inc vs Regeneron Pharmaceuticals Inc — how do they compare? GXO Logistics Inc trades at $54.2 (market cap $6.02B), while Regeneron Pharmaceuticals Inc trades at $678.67 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.6× GXO Logistics Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| GXO | REGN | |
|---|---|---|
Market Cap | $6.02B | $69.66B |
Sector | Industrials | Health |
52-Week High | $65.59 | $812.27 |
52-Week Low | $45.52 | $542.52 |
Enterprise Value | $11.18B | $63.61B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics is trading at $53.36, up 7.43% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamental performance with three consecutive quarterly earnings beats and 10.8% revenue growth in Q1 2026. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $66.60 consensus price target representing 25% upside potential. Recent business developments include multiple partnership renewals and expansion into strategic verticals like aerospace and defense.
GXO presents a compelling investment opportunity with strong earnings momentum and institutional support, though investors should monitor competitive pressures from Amazon's logistics expansion and the company's transition toward higher-margin verticals. The stock's current valuation at 46.69x P/E appears elevated relative to modest net margins, requiring continued execution on growth initiatives to justify premium multiples.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →